Angiographic patency study of anistreplase versus streptokinase in acute myocardial infarction

[1]  W. Hillis,et al.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. , 1988, British heart journal.

[2]  A. M. Skene,et al.  TRIAL OF TISSUE PLASMINOGEN ACTIVATOR FOR MORTALITY REDUCTION IN ACUTE MYOCARDIAL INFARCTION Anglo-Scandinavian Study of Early Thrombolysis (ASSET) , 1988, The Lancet.

[3]  H. Bonnier,et al.  Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction. , 1988, The American journal of cardiology.

[4]  J. Anderson,et al.  Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase. , 1988, Journal of the American College of Cardiology.

[5]  D. Chamberlain,et al.  Vasculitis complicating treatment with intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction. , 1988, British heart journal.

[6]  R. W. Brower,et al.  Acute coronary thrombolysis with recombinant human tissue-type plasminogen activator: initial patency and influence of maintained infusion on reocclusion rate. , 1987, The American journal of cardiology.

[7]  S. Sherry.  Recombinant tissue plasminogen activator (rt-PA): is it the thrombolytic agent of choice for an evolving acute myocardial infarction? , 1987, The American journal of cardiology.

[8]  F H Sheehan,et al.  The effect of intravenous thrombolytic therapy on left ventricular function: a report on tissue-type plasminogen activator and streptokinase from the Thrombolysis in Myocardial Infarction (TIMI Phase I) trial. , 1987, Circulation.

[9]  E. Geltman.  Coronary thrombolysis with intravenous streptokinase. , 1987, Cardiology clinics.

[10]  L. Rosenbaum,et al.  Serum sickness-like illness and leukocytoclastic vasculitis following intracoronary arterial streptokinase. , 1987, American heart journal.

[11]  Gruppo Italiano per lo Studio della Soprawivenza nell'Inf Miocardico..  EFFECTIVENESS OF INTRAVENOUS THROMBOLYTIC TREATMENT IN ACUTE MYOCARDIAL INFARCTION , 1986, The Lancet.

[12]  W. Hillis,et al.  Intracoronary Thrombolytic Therapy Performed within a Coronary Care Unit: One Year's Experience , 1986, Scottish medical journal.

[13]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[14]  R. W. Brower,et al.  RANDOMISED TRIAL OF INTRAVENOUS RECOMBINANT TISSUE-TYPE PLASMINOGEN ACTIVATOR VERSUS INTRAVENOUS STREPTOKINASE IN ACUTE MYOCARDIAL INFARCTION Report from the European Cooperative Study Group for Recombinant Tissue-type Plasminogen Activator , 1985, The Lancet.

[15]  R. Hornung,et al.  Coronary thrombolysis with intravenous anisoylated plasminogen-streptokinase complex BRL 26921. , 1985, British heart journal.

[16]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.

[17]  W. Aronow,et al.  Serum sickness following selective intra-coronary streptokinase , 1984 .

[18]  R. Smith,et al.  Fibrinolysis with acyl-enzymes: a new approach to thrombolytic therapy , 1981, Nature.

[19]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.